At this year’s Fierce Biotech Summit in Boston, we caught up with leaders in the biotech industry who have been recognized as past Fierce 15 honorees. 

These private biotechs have made significant contributions to their field, and their groundbreaking work is shaping the industry's future.

Fierce Biotech’s Gabrielle Masson sat down with Liang Schweizer, Ph.D. founder, chairperson and CEO of HiFiBiO Therapeutics; Adam Friedman, M.D., Ph.D., CEO of Scorpion Therapeutics; and Debanjan Ray CEO of Synthekine. 

In this week’s episode of “The Top Line,” these leaders share their insights, experiences, and visions for the evolving biotech landscape.

To learn more about the topics in this episode: 

• Introducing Fierce Biotech's 2024 Fierce 15

• Scorpion snaps up $150M in series C funds to widen clinical plans for cancer pipeline

• Synthekine hopes new IL-2 will be the high-alpha in a beta class 

See omnystudio.com/listener for privacy information.